Advanced Science | 结直肠癌肝转移患者来源的类器官模型助力临床肿瘤精准治疗

Advanced Science - 2022 - Mo - Patient‐Derived Organoids from Colorectal Cancer

Adv Sci (Weinh). 2022 Nov;9(31):e2204097. doi: 10.1002/advs.202204097. Epub 2022 Sep 4.

There is no effective method to predict chemotherapy response and postoperative prognosis of colorectal cancer liver metastasis (CRLM) patients. Patient-derived organoid (PDO) has become an important preclinical model. Herein, a living biobank with 50 CRLM organoids derived from primary tumors and paired liver metastatic lesions is successfully constructed. CRLM PDOs from the multiomics levels (histopathology, genome, transcriptome and single-cell sequencing) are comprehensively analyzed and confirmed that this organoid platform for CRLM could capture intra- and interpatient heterogeneity. The chemosensitivity data in vitro reveal the potential value of clinical application for PDOs to predict chemotherapy response (FOLFOX or FOLFIRI) and clinical prognosis of CRLM patients. Taken together, CRLM PDOs can be utilized to deliver a potential application for personalized medicine.

来源于结直肠癌肝转移(CRLM)患者原发灶及配对肝转移灶的类器官生物库，并从组织病理学、基因组学、转录组学和单细胞测序等多组学维度分析了该生物库的特征，对类器官生物库队列做出了重要补充；同时还评估了CRLM类器官预测化疗反应和临床预后的有效性，为CRLM来源类器官预测联合药物化疗（FOLFOX/FOLFIRI）提供了进一步的证据支持。

原文链接：https://onlinelibrary.wiley.com/doi/10.1002/advs.202204097